Helminthic Therapy

Hookworm Secreted Biochemicals as Stromal Softeners and Chemosensitizers: A Mechanistic Account for Supportive Use with Chemotherapy

How Necator americanus excretory/secretory products can increase tumor permeability to cytotoxic drugs

Stephen Michael Nenninger, N.M.D.

1. The clinical premise

Patients receiving supportive chemotherapy who also carry a therapeutic colony of Necator americanus have been observed to tolerate and respond to cytotoxic drugs more readily than the same regimens would predict. The working account is that hookworm excretory/secretory (ES) products soften the tumor and its stroma and raise the permeability of malignant cells and the interstitial matrix to chemotherapy. That account is a conjecture. It is a conjecture with a specific biochemical inventory behind it: larval and adult hookworms secrete hyaluronidases, matrix metalloproteases, aspartic and serine proteases, chemokine-mimic proteins that induce edema, anticoagulants that decompress tumor vasculature, and vesicles that rewrite epithelial phenotype. Each of those classes has an independent literature showing increased drug access or increased tumor-cell kill when combined with a cytotoxic agent.

2. Softening the stroma: matrix enzymes the worm already uses to cross tissue

Third-stage larvae of N. americanus enter skin by secreting aspartic, serine, and metalloproteinases that degrade collagen, elastin, and fibronectin.1 Recombinant Ancylostoma metalloprotease MTP-1 digests gelatin, collagen, laminin, and fibronectin; antibody or chelator blockade of that enzyme cuts larval tissue migration by 70 percent.2 Adult hookworm ES contains additional cysteine, aspartic, and serine proteinases and a metalloproteinase with anticoagulant activity.3 Larvae of Ancylostoma further secrete hyaluronidase that hydrolyzes hyaluronic acid in epidermal and dermal ground substance.4 Those are the same matrix components that wall off solid tumors. Hyaluronan accumulation raises interstitial fluid pressure, compresses vessels, and blocks macromolecular drug entry. Enzymatic removal of hyaluronan with PEGylated hyaluronidase (PEGPH20) lowers that pressure, re-opens vessels, and increases chemotherapy delivery in preclinical models — a principle first used clinically in the 1950s when hyaluronidase was given with cytotoxic drugs as a “spreading factor.”5 A living hookworm is a continuous, low-dose source of the same class of enzymes. The conjecture is that those enzymes nibble the tumor-associated matrix the way they nibble dermis, lowering the mechanical and hydraulic barrier between capillary and malignant cell.

Na-ASP-2, a chemokine-fold protein secreted at the free-living-to-host-adapted transition, recruits neutrophils and monocytes and produces local edema. That edema increases tissue permeability.6 A related nematode, Heligmosomoides polygyrus, secretes a heat-stable 10–50 kDa factor, identified as a secretory phospholipase A2 acting through epithelial EP2 and EP4 receptors, that measurably increases intestinal epithelial permeability in vitro.7 Hookworms therefore possess both enzymatic cutters of matrix and lipid mediators that open epithelial junctions. Either action, applied at a tumor bed or at a mucosal tumor, is a permeability event.

3. Softening the malignant cell: EMT reversal and membrane phenotype

Antigen from the hookworm-model nematode Nippostrongylus brasiliensis reduces cervical-cancer cell migration and lowers global and cell-surface vimentin and N-cadherin. The same antigen reduces HPV-16 pseudovirion internalization. Live colonization lowers vimentin in the female genital tract.8 Vimentin and N-cadherin are canonical epithelial–mesenchymal transition (EMT) markers. EMT stiffens invasive behavior, raises drug efflux, and thickens the mesenchymal coat that keeps cytotoxics out. Reversing those markers is a form of cellular softening: the cell becomes less migratory and, in other EMT-reversal systems, more chemosensitive. The hookworm antigen result is the closest direct evidence that a hookworm biochemical changes the mechanical and surface phenotype of a human cancer cell.

4. Hookworm anticoagulants open vessels and add to 5-fluorouracil

Adult hookworms secrete nematode anticoagulant protein c2 (NAPc2), an 85-residue inhibitor of the tissue-factor/factor VIIa complex, and Ancylostoma caninum anticoagulant peptide (AcAP), a picomolar factor-Xa inhibitor.9 Tissue factor is overexpressed on colorectal and other carcinomas and tracks with stage. Recombinant NAPc2 inhibited CT26 pulmonary metastasis in a dose-dependent manner. In HCT116 xenografts, rNAPc2 alone cut tumor volume 33 percent; 5-fluorouracil alone cut it 54 percent; the combination cut it 81 percent and simultaneously reduced microvessel density. The same additive pattern held with bevacizumab (61 percent versus 88 percent combined). rNAPc2 plus irinotecan reduced hepatic metastasis. The effect required tissue factor on the tumor cells.10 rAcAP given before tail-vein injection of LOX melanoma reduced lung metastases and blocked factor-Xa binding to the tumor cell surface.11 Decompressing coagulation-driven vasculature and stripping factor Xa from the tumor membrane are permeability events in the vascular compartment: more drug reaches the interstitium, and the cell surface is less occupied by clotting proteins that shield it.

5. Helminth ES products already potentiate 5-fluorouracil in vivo

The tightest chemotherapy-combination data come from a related helminth secretome. Excreted/secreted products of Taenia crassiceps (TcES) plus 5-fluorouracil reduced established colitis-associated colon-tumor load by 70 percent. 5-Fluorouracil alone reduced load 15 percent; TcES alone reduced it 40 percent.12 The combination downregulated Il-10 and Tgf-β at the tumor, lowered TNF-α and IL-17A, reduced cyclin D1 and Ki67, restored p53 by lowering Mdm2, recruited NK cells, and deposited granzyme B in the tumor bed. On HCT116 and RKO cells the same pairing cut proliferation and migration through p53/p21. Recombinant Taenia solium calreticulin likewise synergized with 5-fluorouracil.13 Hookworms secrete their own calreticulin, which binds C1q.14 They also secrete a protein that binds human NK cells and, with IL-2 and IL-12, raises IFN-γ 4- to 30-fold.15 Chemotherapy that kills tumor cells immunogenically therefore meets a worm-primed NK compartment. That is a second, immunological permeability: the dying cell is more visible.

6. Conjectural synthesis: three physical compartments of “softening”

Matrix. Larval and adult proteases and hyaluronidase lower hyaluronan, collagen, laminin, and fibronectin in and around the tumor. Interstitial pressure falls. Vessels reopen. Small-molecule cytotoxics and antibodies move farther from the capillary. This is the PEGPH20 mechanism executed by a living secretory source.2,4,5

Vessel and cell surface. NAPc2 and AcAP release the tissue-factor/Xa clamp on tumor endothelium and on the malignant membrane. Edema from Na-ASP-2 and EP2/EP4-dependent lipid mediators from related nematodes open junctions.6,7,10 Drug flux into the interstitium and across the plasma membrane rises.

Phenotype and kill-switch. Hookworm antigen reverses EMT markers and reduces surface vimentin.8 Helminth ES plus 5-fluorouracil restores p53, drops Mdm2, and recruits granzyme-B-competent NK cells.12,15 The cell is less mesenchymal and more apoptotic once the drug is inside. That is permeability of the death program, not only of the membrane.

Epidemiology is consistent with a net antitumor bias for soil-transmitted helminths as a class: historical maps of hookworm and related helminth prevalence invert with pancreatic-cancer incidence.16 The molecules that would produce that bias — matrix enzymes, anticoagulants, EMT-reversing antigens, NK-binding ES proteins — are the same molecules a therapeutic N. americanus colony secretes every hour it is attached. Used beside supportive chemotherapy, they are predicted to raise the fraction of administered drug that reaches and kills the malignant cell without any requirement that the worm itself be cytotoxic.

The model is testable. Paired tumor explants or circulating tumor cells taken before and after colonization should show lower interstitial hyaluronan and collagen, higher intra-tumoral concentrations of the co-administered cytotoxic at equal plasma AUC, lower surface vimentin, and higher cleaved caspase-3 per unit drug. Cross-over of ES-depleted versus ES-replete larvae would isolate secretion as the causal compartment.

References

  1. Brown A, et al. Ancylostoma caninum metalloproteinase. 1999. Reviewed in EMBO J. 2026.
  2. Williamson AL, et al. Hookworm Ac-MTP-1 degrades collagen, laminin, and fibronectin and is required for tissue migration. Infect Immun. 2006;74:961–967.
  3. Brown A, et al. Proteolytic enzymes of adult Necator americanus. 1995. Hotez PJ, Cerami A. Hookworm anticoagulant metalloproteinase. 1983.
  4. Hotez PJ, et al. Hyaluronidase from third-stage Ancylostoma larvae. Infect Immun. 1992;60:1018–1023.
  5. Provenzano PP, Hingorani SR. Hyaluronan, interstitial pressure, and drug delivery. Whatcott CJ, et al. Targeting hyaluronan in the tumor stroma. 2011. Early clinical hyaluronidase-plus-chemotherapy: 1950s spreading-factor literature.
  6. Bower MA, et al. Na-ASP-2 induces neutrophil-rich infiltrate and tissue permeability. 2008. Recapitulated in EMBO J. 2026.
  7. Reed EK. H. polygyrus secretory PLA2 increases epithelial permeability via EP2/EP4. Doctoral thesis, Cardiff University. 2025.
  8. Jacobs BA, et al. Hookworm exposure decreases HPV uptake and cervical cancer cell migration through regulation of EMT markers. Sci Rep. 2018;8:11547.
  9. Stassens P, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA. 1996. Abuzeid AMI, et al. Twenty-five-year progress in hookworm ES products. 2020.
  10. Zhao J, et al. rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009;15:208–216. Additive with 5-FU (81.3% versus 32.7% and 53.7%) and with bevacizumab.
  11. Donnelly KM, et al. Ancylostoma caninum anticoagulant peptide blocks melanoma metastasis and factor Xa binding. Thromb Haemost. 1998;79:1041–1047.
  12. Meneses G, et al. Helminth-derived molecules improve 5-fluorouracil treatment on experimental colon tumorigenesis. 2024. Combined TcES+5-FU reduced tumor load 70% versus 15% (5-FU) and 40% (TcES).
  13. Reviewed in: The impact of helminths on colorectal cancer. Pathogens. 2025;14:949. Helminth molecules in cancer therapy. Front Immunol. 2026.
  14. Kasper G, et al. Necator calreticulin interacts with C1q. 2001.
  15. Hsieh GC, et al. A secreted Necator protein binds NK cells and induces IFN-γ. J Immunol. 2004;173:2699–2704.
  16. Shor E, et al. Inverse correlation between soil-transmitted helminths and pancreatic cancer. 2021. Oikonomopoulou K, et al. Revaluation of the hygiene hypothesis in malignancy. Clin Cancer Res. 2013.